Characteristics of patients with major depressive disorder eligible for and prescribed esketamine, treatment outcomes and physician experiences: a physician and patient survey in the United States.
Manish K. Jha, Amanda Teeple, Jason Shepherd, Alexander Gillespie, Nikisha Grant, Ashley Mortimer, Sophie Kirkman, Chloe Middleton-Dalby, Kruti Joshi
Current Medical Research and Opinion February 1, 2025 DOI: 10.1080/03007995.2025.2463975 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 914 |
| Population | Patients with treatment-resistant depression (TRD) or major depression with acute suicidal ideation or behavior (MDSI) in the US |
| Intervention | Esketamine |
| Topics | Depression Esketamine |
| Keywords | Quality of life Treatment outcome Depression treatment Mental health breakthroughs Esketamine therapy Clinical outcomes |
| Key findings | Patients with TRD and MDSI experience substantial daily-life impairment that physicians underestimate, and esketamine-treated patients show improvements in clinical global impression and activities of daily living. |
Abstract
Esketamine is an FDA-approved treatment for treatment-resistant depression (TRD) or major depression with acute suicidal ideation or behavior (MDSI). This analysis addressed the lack of data on real-world characteristics of patients with TRD and MDSI or prescribed esketamine. Data were derived from the Adelphi Real World Depression Disease Specific Programme a cross-sectional survey of physicians and patients with TRD, MDSI, or those prescribed esketamine in the US (July 2022-February 2023). Physicians reported demographic and clinical characteristics, patients completed PHQ-9 and WPAI measures. Of 914 patients enrolled in the survey, 66.2% had TRD and 33.8% MDSI. Mean (± standard deviation) PHQ-9 scores were 8.3 ± 6.3 (TRD) and 9.3 ± 6.3 (MDSI), with moderate-to-very severe depression reported by 36.5% (TRD) and 48.3% (MDSI) of patients. Mean work impairment was 26.0 ± 28.1% and overall impairment 34.7 ± 27.3%. No-to-mild impairment was reported for most patients in ability to meet basic needs, social functioning, work, overall quality of life and general health. Patients and physicians showed low levels of agreement on disease severity and trajectory. Patients prescribed esketamine (n = 94) were 43.3 ± 13.3 years old, diagnosed 5.7 ± 6.6 years before survey, sex was evenly split, and 64.8% were working full or part time. Most common diagnoses were TRD (38.3%), MDD (37.2%) or MDSI (17.0%). Patients showed improvements in CGI-S (64.6-77.8%) and activities of daily living (34-67%) following esketamine. The substantial impact of TRD and MDSI on daily life and unmet treatment need was underestimated by physicians. Patients treated with esketamine reported favorable outcomes.
Comparable studies
Other cross-sectional and survey studies on esketamine for depression, most cited first.